Jeffrey Allen Bailey's Insider Trades & SAST Disclosures
Jeffrey Allen Bailey's most recent trade in Aurinia Pharmaceuticals Inc was a trade of 18,641 Director Stock Option (right to buy) done . Disclosure was reported to the exchange on Nov. 21, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jeffrey Allen Bailey.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 18,641 | 18,641 | - | - | Director Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 12,135 | 25,491 (0%) | 0% | 0 | Common Shares | |
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 0 | - | - | Restricted Stock Units | |
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Nov 2024 | 17,913 | 17,913 (0%) | 0% | - | Common Stock | |
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Sale of securities on an exchange or to another person at price $ 8.43 per share. | 08 Nov 2024 | 4,557 | 13,356 (0%) | 0% | 8.4 | 38,416 | Common Stock |
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 28,959 | 28,959 | - | - | Stock Option (right to buy) | |
| Aurinia Pharmaceuticals Inc | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Aug 2023 | 17,913 | 17,913 | - | - | Restricted Stock Units | |
| Rein Therapeutics Inc. | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2021 | 96,000 | 96,000 | - | - | Stock Option (right to buy) | |
| Tekla World Healthcare Fund | Jeffrey Allen Bailey | Director | 06 Apr 2021 | 735 | 0 | - | - | Subscription Rights | ||
| Tekla World Healthcare Fund | Jeffrey Allen Bailey | Director | 06 Apr 2021 | 245 | 980 (0%) | 0% | 14.3 | 3,494 | Shares of Beneficial Interest | |
| Rein Therapeutics Inc. | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2020 | 12,500 | 12,500 | - | - | Stock Option (right to buy) | |
| Rein Therapeutics Inc. | Jeffrey Allen Bailey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2020 | 54,500 | 54,500 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges